Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Trifluridine-tipiracil hydrochloride |
Synonyms | |
Therapy Description |
Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth and is FDA approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trifluridine-tipiracil hydrochloride | Lonsurf | TAS-102|TAS102|TAS 102|S 95005|S95005|S-95005 | Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth and is FDA approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03981614 | Phase II | Trifluridine-tipiracil hydrochloride Binimetinib + Palbociclib | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02301117 | Phase I | Trifluridine-tipiracil hydrochloride | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment | Completed | USA | 2 |
NCT05223673 | Phase III | Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) | Recruiting | USA | BEL | 3 |
NCT02602327 | Phase I | Trifluridine-tipiracil hydrochloride | Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases | Completed | USA | 0 |
NCT03844620 | Phase II | Regorafenib Trifluridine-tipiracil hydrochloride Regorafenib + Trifluridine-tipiracil hydrochloride | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT03762161 | Phase II | Trifluridine-tipiracil hydrochloride | A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | Recruiting | USA | 0 |
NCT03992456 | Phase II | Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04073615 | Phase Ib/II | Rivoceranib + Trifluridine-tipiracil hydrochloride Rivoceranib Trifluridine-tipiracil hydrochloride | Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT01916447 | Phase I | Bevacizumab Trifluridine-tipiracil hydrochloride Irinotecan | A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. | Completed | USA | 0 |
NCT04042714 | Phase II | Trifluridine-tipiracil hydrochloride | TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (TAS-102 NEC) | Recruiting | USA | 0 |
NCT04854434 | Phase II | Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | Terminated | USA | 0 |
NCT03520946 | Phase III | Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) | Recruiting | DEU | 0 |
NCT04879368 | Phase III | Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan | RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) | Recruiting | USA | CAN | 5 |
NCT04737187 | Phase III | Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 7 |
NCT02500043 | Phase III | Trifluridine-tipiracil hydrochloride | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 11 |
NCT04776148 | Phase III | Regorafenib Trifluridine-tipiracil hydrochloride Lenvatinib + Pembrolizumab | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | Active, not recruiting | USA | ESP | DEU | CAN | 11 |